Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

918.00 +3.43 (+0.38%)
Official Closing Price Updated: 4:10 PM EDT, Jul 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,359,405
Open 917.89
Bid (Size) 918.20 (1)
Ask (Size) 920.00 (1)
Prev. Close 914.57
Today's Range 912.00 - 928.61
52wk Range 434.34 - 918.50
Shares Outstanding N/A
Dividend Yield 0.49%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Gold Falls Over 1%; HilleVax Shares Plunge
Via Benzinga
3 Overlooked Giants-in-the-Making for Patient Investors
Consider buying into these overlooked growth stocks for long-term profits that will help to boost a portfolio and deliver riches. 
Via InvestorPlace

Performance

YTD
+55.02%
+55.02%
1 Month
+8.00%
+8.00%
3 Month
+18.10%
+18.10%
6 Month
+46.64%
+46.64%
1 Year
+102.58%
+102.58%

More News

Read More
Dow Turns Lower; Myomo Shares Jump
Via Benzinga
Topics Stocks
Exposures US Equities
Stock Market News From Amazon, Nike, McCormick, and More
Via The Motley Fool
What's Going On With Eli Lilly Shares Friday?
Via Benzinga
Smart Money Is Betting Big In LLY Options
Via Benzinga
Here's How Much $100 Invested In Eli Lilly and Co 15 Years Ago Would Be Worth Today
Via Benzinga
Why Is Morphic (MORF) Stock Up 75% Today?
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Morphic Holding, Inc. (Nasdaq - MORF), Desktop Metal, Inc. (NYSE - DM), Alimera Sciences, Inc. (Nasdaq - ALIM), Avangrid, Inc. (NYSE - AGR)
From Brodsky & Smith LLC
Via GlobeNewswire
Eli Lilly's First Biotech Deal Of 2024, Buys Chronic Disease Player Morphic For $3.2B
Via Benzinga
Eli Lilly Snaps Up Morphic At 79% Premium
Via Investor's Business Daily
3 No-Brainer Stocks to Buy in July
Via The Motley Fool
The Next $1 Trillion Stock? Tesla, Warren Buffett's Berkshire Hathaway In The Running
Via Investor's Business Daily
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
Via Benzinga
Topics ETFs
The 7 Best Under $10 Stocks to Buy in July 2024
Via InvestorPlace
Copper, Gold Stocks Sparkle, Among 5 Leaders Near Buy Points
Via Investor's Business Daily
MarketBeat Week in Review – 7/1 - 7/5
Via MarketBeat
Topics Economy
Exposures Interest Rates
GLP-1 Treatments Such As Wegvoy, Mounjaro Cut Obesity-Related Cancer Risks, Study Finds
Via Benzinga
Stock Market: S&P 500, Nasdaq Hit Highs As Tesla Soars, Rate-Cut Hopes Rise: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
Via Investor's Business Daily
Missed Out on Eli Lilly? This Much Smaller Biotech Has 2 Promising Weight Loss Assets in its Portfolio
Via The Motley Fool
3 Highly Rated Biotech Stocks for Your July Buy List
Via InvestorPlace
7 High Priced Stocks That Would Benefit From a Stock Split
Via InvestorPlace
Mounjaro and Zepbound Are Great, but This Is the Real Reason Why Eli Lilly Can Soar Past a $1 Trillion Valuation
Via The Motley Fool
The 3 Best Healthcare Stocks to Buy in July 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.